

# **NEW** *Symbyax*<sup>™</sup>

*Olanzapine and Fluoxetine HCl Capsules*

The **FIRST** and **ONLY** FDA-approved treatment for **bipolar depression**.

SYMBYAX is a combination of olanzapine and fluoxetine HCl in a single, convenient capsule.



Visit **SYMBYAX.com**

For important safety information, see inside and the attached full Prescribing Information.

**Symbyax**<sup>™</sup>  
Olanzapine and Fluoxetine HCl Capsules

*Lilly*

## SYMBYAX-treated patients showed significant improvement compared to placebo on all 10 MADRS items in pooled studies of bipolar depression<sup>1</sup>

MADRS is a widely used rating scale for assessing the severity of depressive mood symptoms:

Apparent sadness ( $P < .001$ )<sup>1</sup>

Reported sadness ( $P < .001$ )<sup>1</sup>

Inner tension ( $P < .001$ )

Reduced sleep ( $P < .001$ )

Reduced appetite ( $P < .007$ )

Concentration difficulties ( $P < .041$ )

Lassitude ( $P < .001$ )<sup>1</sup>

Inability to feel ( $P < .001$ )<sup>1</sup>

Pessimistic thoughts ( $P < .001$ )<sup>1</sup>

Suicidal thoughts ( $P < .005$ )

All P-values are SYMBYAX vs placebo.

Statistical analysis is based on pooled data from 2 independent studies. MADRS is Montgomery-Asberg Depression Rating Scale, consisting of 10 items. **Individual study results:** MADRS items statistically significantly improved in one study compared to placebo included: apparent sadness, reported sadness, reduced sleep, lassitude, inability to feel, and pessimistic thoughts. MADRS items statistically significantly improved in the other study compared to placebo included: apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, lassitude, inability to feel, pessimistic thoughts, and suicidal thoughts.

The efficacy of SYMBYAX in bipolar depression was established in 2 identically designed, 8-week registration trials as measured by baseline-to-endpoint change in MADRS Total Scores.

SYMBYAX is approved for the treatment of bipolar depression.

For important safety information, see inside and the attached full Prescribing Information.

<sup>1</sup> Data on file, Lilly Research Laboratories.

<sup>1</sup> In the pooled results, SYMBYAX was superior to olanzapine monotherapy ( $P < .05$ ) on apparent sadness, reported sadness, lassitude, inability to feel, and pessimistic thoughts.



### Available in a range of options

(olanzapine/fluoxetine HCl) capsules:

- 6 mg/25 mg
- 12 mg/25 mg
- 6 mg/50 mg
- 12 mg/50 mg

Starting dose is generally 6 mg/25 mg, taken once daily in the evening.

Caution should be used when prescribing medications that contain olanzapine or fluoxetine HCl concomitantly with SYMBYAX.

Visit **SYMBYAX.com**

DF30586 PRINTED IN USA; 3000073596 030430 ©2004, ELI LILLY AND COMPANY. ALL RIGHTS RESERVED.  
SYMBYAX is a trademark of Eli Lilly and Company.  
LB

**Symbyax**  
Olanzapine and Fluoxetine HCl Capsules

*Lilly*